ARWR — Arrowhead Pharmaceuticals, Inc.

Summary of Arrowhead Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: $2 million for FY 2025, translating to a loss of $0.01 per share, a significant improvement from a net loss of $599 million in FY 2024.
• Revenue: Totaled $829 million, primarily driven by licensing and collaboration agreements, with $697 million from Sarepta and $130 million from Sanofi for Rodemplo rights in Greater China.
• Operating Expenses: Increased to $731 million from $605 million in FY 2024, largely due to higher R&D expenses ($101 million) and SG&A expenses ($25 million).
• Cash Flow: Net cash provided by operating activities was $180 million, a turnaround from a cash burn of $463 million in the previous year.
• Cash Position: Cash and investments totaled $919 million as of September 30, 2025, up from $681 million the previous year.

2. Strategic Updates and Business Highlights

• FDA Approval of Rodemplo: The company received FDA approval for Rodemplo, its first FDA-approved medicine, indicated for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This marks a significant milestone as Arrowhead transitions to a commercial stage.
• Commercialization Efforts: The drug was launched within a week of approval, supported by the Reliant Rodemplo patient support program, which includes financial assistance and resources for patients.
• Pricing Model: Rodemplo is priced at $60,000 annually, with a commitment to consistent pricing across indications.
• Pipeline Progress: Ongoing development of zidaziran for homozygous familial hypercholesterolemia and Aerodimer PA for atherosclerotic cardiovascular disease. The company also initiated a Phase III trial for ARO MAPT targeting tauopathies.
• Business Development: Secured $200 million from Novartis for a licensing agreement and $200 million milestone from Sarepta for ARO DM1.

3. Forward Guidance and Outlook

• Sales Impact: While the launch of Rodemplo is seen as transformative, the company does not anticipate significant commercial sales impact in FY 2026.
• Clinical Trials: Expecting top-line data from ongoing Phase III studies (Shasta 3 and Shasta 4) in mid-2026, with an sNDA submission planned by the end of 2026.
• Cash Runway: The current cash position is projected to sustain operations through FY 2028, even without additional capital.

4. Bad News, Challenges, or Points of Concern

• Market Adoption: The company faces the challenge of establishing market access and adoption for Rodemplo, particularly given the high pricing and the need for payer acceptance.
• Regulatory Uncertainty: There is uncertainty regarding the FDA's requirements for future pancreatitis risk reduction claims, which could impact market positioning.
• Clinical Trial Risks: The success of ongoing trials, particularly for Shasta 3 and Shasta 4, is critical, and there are concerns about the adequacy of powering for pancreatitis outcomes in these studies.

5. Notable Q&A Insights

• Acute Pancreatitis Study Design: Management clarified that while Shasta 3 and 4 were not specifically powered for pancreatitis, they believe there is reasonable power to show a difference. Shasta 5 is designed specifically to assess pancreatitis risk.
• Obesity Programs: Initial data from ARO Inhibit E and ARO ALK7 will be shared in early 2026, with expectations for significant insights into safety and efficacy.
• Dimer Program Potential: The dual-action Aerodimer PA could address both LDL and triglycerides in mixed hyperlipidemia, a significant unmet need in the market.
• Market Strategy: The company aims for a strong launch of Rodemplo, emphasizing its unique attributes and the support program to enhance patient access.

This summary encapsulates the key aspects of Arrowhead Pharmaceuticals' Q4 2025 earnings call, highlighting financial performance, strategic initiatives, and potential challenges ahead.